Mahmood Majeed, ZS, explains why measurable AI outcomes in pharma supply chain and manufacturing jumped from 29% to 53%, and how GMP limits and GxP validation shape adoption.
News|Articles|December 2, 2018
- Pharmaceutical Technology-12-02-2018
- Volume 42
- Issue 12
Mobile App for Supply-Chain Traceability
Adents' DispaX offers improved supply-chain traceability for pharmaceutical warehouses, wholesalers, distributors, and dispensers such as pharmacies and hospitals.
DispaX is a mobile application from Adents developed for pharmaceutical warehouses, wholesalers, distributors, and dispensers such as pharmacies and hospitals for improved supply-chain traceability.
The solution offers three ways to search data: scanning a label, entering a serial or delivery number, or entering a lot number. The application allows all supply chain stakeholders to verify, decommission, and aggregate serialized products at various stages of the supply chain and complies with local regulations in a number of geographies worldwide, according to the company. The application enables users to query by lot, delivery number, serial number, and levels up and down the hierarchy tree. Features include the ability to see all details of an item, navigate up and down parent-child aggregation relationships, manage the products picking, and view shipment history.
Articles in this issue
almost 8 years ago
Sterile, Integrated Hood and Mask for Larger Heads and Hairstylesalmost 8 years ago
Scaling Up and Launching Solid-Dosage Drugsalmost 8 years ago
Developing and Manufacturing Transdermal Patchesalmost 8 years ago
Spray Film Provides Alternative to Patchesalmost 8 years ago
Improving Production: How IT, OT, and Quality Can Collaboratealmost 8 years ago
Manufacturing Considerations for Transdermal Delivery Systemsalmost 8 years ago
Investigation Timeliness vs. Thoroughness: Finding the Right Balancealmost 8 years ago
Microbial Identification Strategies for Bioburden Controlalmost 8 years ago
Fighting Bacterial Resistance with Biologicsalmost 8 years ago
The Key Word: QualityRelated to this article
Shubhajit Paul, a senior research fellow in Boehringer Ingelheim’s Department of Material Analytical Sciences, spoke with PharmTech at AAPS PharmSci 360 to explain how tabletability prediction can be improved for roller-compacted formulations.
This week on PharmTech.com, experts discussed E&L suitability standards, rare disease treatment development, sourcing ingredient suppliers, the use of AI in quality control, and more.
Cole and Jaenisch dig into AI poisoning in pharma manufacturing, how it hides in plain sight, and who should be accountable for catching it.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
Trending on Pharmaceutical Technology
1
Pharma Leaders Weigh in On AI's Measurable Results In 2026
2
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
3
Manufacturing Intelligence: How AI Poisoning Hides in Plain Sight
4
Why BMS, Roche, and LGM Pharma Outsourced Key Capabilities
5